Cialis vs Vardenafil (Levitra/Staxyn): Titration Speed and Tolerability Compared

How PDE5 Inhibitors Work and Why Titration Matters

Both tadalafil and vardenafil block phosphodiesterase type 5, the enzyme that degrades cyclic GMP in penile smooth muscle. Higher cyclic GMP relaxes smooth muscle, increases blood flow, and allows an erection in response to sexual stimulation. Neither drug produces erections without stimulation.

Titration matters because every patient metabolizes these drugs differently. Starting at the lowest effective dose, then adjusting upward, reduces side-effect exposure and identifies the minimum dose that works. The FDA-approved titration ladder is two steps for both drugs: 10 mg then 20 mg for on-demand use, or 2.5 mg then 5 mg for tadalafil daily dosing. Getting titration right the first time lowers the dropout rate, which runs as high as 50% in some real-world ED cohorts within 12 months of starting therapy.

The PDE5 Selectivity Difference

Vardenafil is roughly 10-fold more selective for PDE5 over PDE6 than sildenafil, and tadalafil is also PDE6-sparing relative to sildenafil. PDE6 inhibition drives the visual blue-tinge side effect common with sildenafil. Both tadalafil and vardenafil produce fewer visual complaints than sildenafil because of this selectivity, but vardenafil's PDE5/PDE6 ratio is approximately 1,000:1, giving it a slight tolerability advantage on this specific side effect.

Why Protein Binding Affects How You Titrate

Tadalafil is 94% protein-bound and has a half-life of approximately 17.5 hours. Vardenafil is 95% protein-bound but clears in 4 to 5 hours. That pharmacokinetic gap is the main reason tadalafil can be dosed daily at 5 mg without accumulation issues, while vardenafil is used on demand. It also means a patient switching from tadalafil to vardenafil needs to allow at least 24 hours for tadalafil levels to drop before taking the first vardenafil dose to avoid additive vasodilation.

Titration Speed: Which Drug Reaches Effective Dose Faster?

Titration speed refers to how quickly a patient can move from the starting dose to the dose that reliably works for them. Vardenafil reaches a therapeutic plasma peak in roughly 40 to 60 minutes after oral dosing; tadalafil peaks at 2 hours but sustains therapeutic levels far longer. In a phase III randomized trial by Porst et al. (N=580), vardenafil 10 mg and 20 mg both produced statistically significant improvements in IIEF erectile function domain scores vs. Placebo after just four weeks of on-demand use, suggesting that many patients identify their effective dose within the first two to four attempts.

Tadalafil Titration Steps

The FDA-approved on-demand starting dose of tadalafil is 10 mg taken at least 30 minutes before sexual activity. If 10 mg is insufficient after two to three attempts, the prescriber increases to 20 mg. For daily dosing, the start is 2.5 mg once daily; if the patient does not see improvement after 2 to 4 weeks, the dose moves to 5 mg. The FDA label for tadalafil specifies that no more than one dose should be taken in a 24-hour period for on-demand use.

Because tadalafil stays active for up to 36 hours, a patient can make a meaningful dose-effectiveness judgment after just two or three doses taken on separate days. That compressed assessment window is one clinical advantage of its long half-life.

Vardenafil Titration Steps

Vardenafil (Levitra) starts at 10 mg approximately 60 minutes before sexual activity, adjustable to 5 mg or 20 mg based on tolerability. The FDA label for vardenafil notes that the maximum recommended dosing frequency is once per day. Staxyn, the orally disintegrating formulation, is available only in the 10 mg dose and should not be substituted milligram-for-milligram for Levitra tablets because bioavailability differs.

A patient who experiences flushing or mild hypotension at 10 mg vardenafil can be down-titrated to 5 mg, which is not a standard step with tadalafil on-demand (the label does not formally list 5 mg on-demand). This gives vardenafil a small advantage in dose flexibility for patients who are sensitive to vasodilatory side effects.

Side-Effect Profiles: Where the Two Drugs Diverge

Both drugs share the same class-wide side effects: headache, facial flushing, nasal congestion, and dyspepsia. These arise from PDE5 inhibition in vascular beds outside the penis. The clinically meaningful differences are in visual effects, back pain, and cardiovascular blood pressure impact.

Headache and Flushing

In the landmark Brock et al. Randomized controlled trial of tadalafil (N=179), headache occurred in 14% of tadalafil-treated patients vs. 4% placebo, and flushing in 5% vs. 1%. Brock et al. (J Urol 2002) confirmed tadalafil 20 mg improved IIEF scores by 6.3 points vs. 1.1 points for placebo (P<0.001), with a side-effect profile that remained consistent across the titration period.

Vardenafil carries a similar headache rate. In Porst et al. (Int J Impot Res 2003), headache occurred in approximately 16% of vardenafil 20 mg patients vs. 4% placebo. Flushing was reported in 12% at the 20 mg dose. Porst et al. Showed IIEF erectile function domain scores improved by 8.0 points with vardenafil 20 mg vs. 1.4 points with placebo (P<0.001).

Back Pain and Myalgia

Back pain and muscle aches are reported with tadalafil at rates of 6 to 9% in clinical trials, a side effect attributed to inhibition of PDE11, an enzyme expressed in skeletal muscle. The tadalafil FDA label identifies back pain and myalgia as adverse reactions occurring in ≥2% of patients and more frequently than placebo. Vardenafil has negligible PDE11 activity and carries a substantially lower rate of back pain, making it the preferable choice for patients who find musculoskeletal side effects intolerable.

Visual Side Effects

Tadalafil inhibits PDE11 but has relatively low PDE6 selectivity compared to vardenafil. Vardenafil's approximately 1,000:1 PDE5-to-PDE6 ratio means visual disturbances (blue-tinge, altered light perception) are infrequent. A comparative review published via NIH noted that vardenafil's high PDE5/PDE6 selectivity translates to a favorable visual tolerability profile relative to other PDE5 inhibitors. Patients who previously experienced visual changes on sildenafil or who have retinal concerns may tolerate vardenafil better.

Blood Pressure Effects

Both drugs lower systolic blood pressure by approximately 6 to 10 mmHg in normotensive men. A study published through PubMed examining PDE5 inhibitor hemodynamic effects found that vardenafil and tadalafil produced comparable mild reductions in blood pressure, with no clinically significant difference in healthy volunteers. Both are contraindicated with nitrates; both require caution with alpha-blockers. The key distinction: tadalafil's 36-hour duration means its blood pressure effect persists longer per dose, a relevant factor for patients on antihypertensives.

Onset of Action: Which Works Faster?

Speed of onset is a common patient concern and a frequent reason men request a switch between PDE5 inhibitors.

Tadalafil Onset

Tadalafil reaches sufficient plasma concentration for clinical effect in most men within 30 minutes of ingestion, though peak concentration takes about 2 hours. The NIH MedlinePlus drug information for tadalafil notes that the drug may be taken 30 minutes to 36 hours before sexual activity. A high-fat meal does not meaningfully affect tadalafil absorption, which is a practical advantage for patients who cannot time dosing around meals.

Vardenafil Onset

Vardenafil reaches detectable effect in 15 to 25 minutes in pharmacokinetic studies. A high-fat meal delays absorption and reduces peak concentration by approximately 20%, so the package insert recommends avoiding high-fat meals close to dosing. The FDA-approved vardenafil label states that sexual stimulation is required and that the drug should be taken approximately 60 minutes before activity for optimal results. Staxyn (orally disintegrating vardenafil) dissolves under the tongue without water and may have a slight subjective onset advantage, though formal comparative pharmacokinetic data against Levitra tablets is limited.

Duration of Action: Planning Sexual Activity

Tadalafil's 36-Hour Window

This is tadalafil's single largest differentiator. Patients who prefer spontaneous sex without clock-watching consistently rate tadalafil more favorably on this dimension. At 5 mg daily, plasma levels remain stable enough that the dosing interval does not create a window of reduced efficacy, effectively making the drug continuously available. A randomized placebo-controlled trial published on PubMed demonstrated that once-daily tadalafil 5 mg significantly improved IIEF erectile function domain scores vs. Placebo over 12 weeks (P<0.001), with consistent efficacy regardless of the time of sexual activity.

Vardenafil's 4 to 6-Hour Window

Vardenafil's shorter duration is not a deficiency for patients who prefer a defined period of activity. Some men and their partners prefer knowing the drug is active for a specific, predictable window rather than for a day and a half. The 4 to 6 hour window also means that cardiovascular side effects, if they occur, resolve faster.

Drug Interactions and Contraindications

Both drugs share several absolute contraindications and dose-reduction requirements.

Nitrate Interaction

Concurrent use of any nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) with either drug is absolutely contraindicated because of the risk of severe, potentially fatal hypotension. The FDA has issued labeling requirements for all PDE5 inhibitors prohibiting co-administration with nitrates in any form.

CYP3A4 Inhibitors

Both drugs are metabolized via CYP3A4. Potent inhibitors (ketoconazole, ritonavir, itraconazole) increase plasma concentrations significantly. The vardenafil FDA label specifies a maximum single dose of 2.5 mg vardenafil within a 72-hour period when co-administered with ritonavir. Tadalafil requires a similar dose cap with potent CYP3A4 inhibitors. Patients on HIV protease inhibitors or antifungal azoles need dose adjustment regardless of which PDE5 inhibitor they use.

QT Prolongation Risk

Vardenafil carries an FDA warning about QT prolongation not shared to the same degree with tadalafil. The vardenafil label states it should be avoided in patients with congenital long QT syndrome and in those taking Class IA or III antiarrhythmics. This is a clinically meaningful difference. Patients on amiodarone, sotalol, quinidine, or procainamide should use tadalafil instead.

Switching from Cialis to Vardenafil: Clinical Protocol

Patients switch between PDE5 inhibitors for several reasons: intolerable back pain on tadalafil, preference for a shorter action window, cost differences, or loss of efficacy at maximum dose. A review of PDE5 inhibitor cross-prescribing patterns published via PubMed found that approximately 30 to 40% of men who discontinue one PDE5 inhibitor will try another within 12 months.

When to Consider the Switch

Back pain or myalgia on tadalafil is the most clinically clear indication to try vardenafil, given vardenafil's near-zero PDE11 activity. Visual side effects on sildenafil that prompted a move to tadalafil are not typically a reason to switch to vardenafil, since both tadalafil and vardenafil are PDE6-sparing relative to sildenafil. QT prolongation risk on an antiarrhythmic? Stay on tadalafil.

Washout Period

Because tadalafil has a 17.5-hour half-life, five half-lives equals approximately 87.5 hours. A clinical washout of 24 to 48 hours before the first vardenafil dose is the minimum; waiting 72 hours is more conservative and appropriate for patients on higher-dose tadalafil (20 mg). The FDA recommends that clinicians review the complete list of drug interactions before switching patients between PDE5 inhibitors.

Starting Dose After Switch

Begin vardenafil at 10 mg, regardless of the tadalafil dose the patient was using. Receptor sensitivity resets within the washout window, so there is no justification for starting at 20 mg based on prior tadalafil tolerance. If 10 mg is well-tolerated and insufficient, advance to 20 mg after two to three attempts.

Who Should Use Which Drug: A Clinical Decision Guide

No head-to-head randomized trial has directly compared tadalafil vs. Vardenafil on patient preference as a primary endpoint. The guidance below draws from their pharmacological differences and the accumulated trial evidence.

Tadalafil Is Generally Preferred When:

• The patient wants spontaneous sex without timing pressure.
• Daily dosing is preferred for psychological comfort or relationship reasons.
• The patient is on a stable antiarrhythmic that prolongs QT.
• High-fat meals cannot easily be avoided near dosing time.

Vardenafil Is Generally Preferred When:

• Back pain or myalgia occurred on tadalafil.
• The patient prefers a defined, shorter activity window.
• Visual side effects are a concern (historically; more relevant in patients switching from sildenafil).
• A lower starting dose (5 mg) is needed due to hypotension sensitivity, and 5 mg on-demand tadalafil is not on-label.

The American Urological Association guideline on erectile dysfunction states that all approved PDE5 inhibitors are appropriate first-line therapy for most men with ED, with drug selection individualized based on patient preference, side-effect profile, and dosing convenience. That individualization process is exactly what the clinical comparisons above are meant to support.

Men With Diabetes or Post-Prostatectomy ED

Both drugs show reduced absolute response rates in men with diabetic ED compared to the general ED population. A PubMed-indexed analysis of PDE5 inhibitor efficacy in men with type 2 diabetes found that IIEF domain score improvements were approximately 30 to 40% lower than in nondiabetic cohorts, regardless of which PDE5 inhibitor was used. For post-radical-prostatectomy patients with nerve-sparing surgery, tadalafil daily dosing has the most strong trial evidence for penile rehabilitation, though vardenafil has also been studied in this context.

Cost, Availability, and Generic Options

Generic tadalafil has been available in the United States since 2018 and now costs approximately $1, $4 per tablet at most pharmacies depending on dose and supplier. Generic vardenafil (generic Levitra) became available in the United States after 2018 as well, with similar pricing. Staxyn (orally disintegrating vardenafil) remains branded and substantially more expensive; a 30-tablet supply may cost $400, $600 without insurance.

The FDA's Orange Book confirms both generic tadalafil and generic vardenafil as therapeutically equivalent to their brand-name counterparts. Clinically, generic substitution is appropriate for most patients.